VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
RAPP
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
RAPPRapport Therapeutics, Inc. Common Stock
$23.40$1.1B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. RAPP
  4. Financial Ratios

Rapport Therapeutics, Inc. Common Stock (RAPP) Financial Ratios

Latest Ratios: P/E Ratio -7.4x · EV/EBITDA N/A · ROE -28.2%. (2022–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

RAPP Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022
Market Cap$1.1B$1.2B$368M——
Enterprise Value$1.1B$1.1B$313M——
P/E Ratio →-7.43————
P/S Ratio55.96————
P/B Ratio1.882.441.20——
P/FCF—————
P/OCF—————

P/E links to full P/E history page with 30-year chart

RAPP EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022
EV / Revenue—————
EV / EBITDA—————
EV / EBIT—————
EV / FCF—————

RAPP Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022
Gross Margin—————
Operating Margin—————
Net Profit Margin—————

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022
ROE-28.2%-28.2%-56.0%—-54.6%
ROA-26.9%-26.9%-33.3%-37.2%-33.7%
ROIC-27.1%-27.1%-79.6%——
ROCE-31.3%-31.3%-36.7%-41.0%-34.6%

RAPP Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022
Debt / Equity0.020.020.00—0.53
Debt / EBITDA—————
Net Debt / Equity—-0.08-0.18—-1.06
Net Debt / EBITDA—————
Debt / FCF—————
Interest Coverage————-36.38

Net cash position: cash ($53M) exceeds total debt ($11M)

RAPP Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022
Current Ratio26.1726.1735.3417.1418.80
Quick Ratio26.1726.1735.3417.1418.80
Cash Ratio25.7525.7534.8216.7518.74
Asset Turnover—————
Inventory Turnover—————
Days Sales Outstanding—————

RAPP Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022
Dividend Yield—————
Payout Ratio—————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022
Earnings Yield—————
FCF Yield—————
Buyback Yield0.0%0.0%0.0%——
Total Shareholder Yield0.0%0.0%0.0%——
Shares Outstanding—$39M$21M$2M$20M

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Equity dilution funding dependence

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Premium Valuation Without Earnings Support

Based on reported figures, RAPP trades at 58.44 times sales and 1.96 times book value while earning negative returns, so the market is pricing pipeline optionality rather than current earnings power or revenue scale. This gap between price and fundamentals is typical of pre-revenue biotech and leaves the stock sensitive to trial readouts.

A price-to-sales multiple above 58 is only meaningful for a company with a commercial revenue base, and RAPP has none, so the metric mainly reflects the market's assessment of the RAP-219 program. The 1.96 price-to-book ratio is more informative here, suggesting the market values the platform at roughly twice the stated equity base of $391.2M. Investors should monitor whether pivotal data can justify that premium before dilution erodes per-share value.

Minimal Debt Masks Equity Erosion

As reported in the balance sheet, RAPP's debt-to-equity ratio of 0.02 looks conservative, yet equity has fallen to $391.2M as the accumulated deficit reached -$351.9M, indicating the capital base is shrinking through losses.

A near-zero leverage ratio reflects the absence of debt rather than balance sheet strength, since the company has no earnings to cover interest and no debt service capacity is being tested. The more relevant pressure is the steady erosion of equity, which suggests future capital needs will likely be met through issuance. Interest coverage is not meaningful given the lack of operating income.

Cash Cover Measured in Quarters

According to reported financials, RAPP's current ratio of 20.07 reflects a large current asset base against minimal liabilities, but $74.8M in cash against a $41.6M quarterly operating outflow implies only about two quarters of coverage at current burn.

The very high current ratio is a function of a small liability base rather than abundant excess liquidity, so it overstates the cushion available to fund trials. Stress testing liquidity against the most recent burn rate indicates the position could tighten quickly as pivotal activity ramps. The quick ratio tracks the current ratio exactly, consistent with negligible inventory, so liquidity depends entirely on cash and equity access.

Negative Returns Driven by Clinical Burn

Based on reported figures, RAPP's ROE of -9.9% and ROIC of -9.5% in 2026Q3 are negative and have deteriorated from the -4.2% ROE recorded in 2026Q1, reflecting losses that are growing faster than the capital base.

Negative ROIC is expected for a clinical-stage company, but the trend matters: returns have moved deeper into negative territory as R&D spend ramped toward roughly $51M per quarter. Because the denominator is a shrinking equity base, ROE can look less severe than the underlying loss trajectory suggests. These ratios should be read as a measure of capital consumption rather than a failure of capital efficiency at this stage.

Lagging Peers on Returns, Leading on Balance Sheet

Compared with peers such as ACADIA at 28.0% ROE and INVA at 15.8% ROE, RAPP's negative returns and 0.02 debt-to-equity place it at the opposite end of the profitability spectrum, though its leverage is among the lowest in the group.

The return gap is structural to RAPP's pre-revenue stage rather than a temporary execution problem, since peers generate earnings from commercial operations. Its low leverage is a genuine strength relative to the group, but it reflects the absence of debt financing rather than a deliberate capital structure advantage. The relevant comparison for RAPP is with other clinical-stage CNS developers, where it should be judged on pipeline progress and cash runway.

Misapplied Gross Margin Metric

The ratio most commonly misapplied to RAPP is the price-to-sales multiple, which appears inflated at 58.44 times on negligible revenue and obscures the cash burn that actually drives valuation risk.

Applying sales-based multiples to a company whose revenue is a single non-recurring quarter of $20.0M produces a figure that reflects the market's optionality on RAP-219 rather than any revenue base. A more appropriate lens is cash runway per share and the probability-weighted value of pivotal readouts, since these capture the equity dilution path. Investors should monitor quarterly operating outflows against the $74.8M cash balance to assess how much time remains before financing is required.

Download Financial Ratios Data

Includes 30+ ratios · 4 years · Updated daily

Consensus & Technical Research Suite
Open RAPP Terminal

RAPP Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

RAPP — Frequently Asked Questions

Quick answers to the most common questions about buying RAPP stock.

What is Rapport Therapeutics, Inc. Common Stock's P/E ratio?

Rapport Therapeutics, Inc. Common Stock's current P/E ratio is -7.4x. This places it at the 50th percentile of its historical range.

What is Rapport Therapeutics, Inc. Common Stock's ROE?

Rapport Therapeutics, Inc. Common Stock's return on equity (ROE) is -28.2%. The historical average is -46.3%.

Is RAPP stock overvalued?

Based on historical data, Rapport Therapeutics, Inc. Common Stock is trading at a P/E of -7.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.